Drug, bio-affecting and body treating compositions patents - Monitor Patents
FreshPatents.com Logo    FreshPatents.com icons
Monitor Keywords Patent Organizer File a Provisional Patent Browse Inventors Browse Industry Browse Agents



USPTO Class 424  |  Browse by Industry: Previous - Next | All     monitor keywords
Recent  |  14: Jul | Jun | May | Apr | Mar | Feb | Jan | 13: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 12: Dec | Nov | Oct | Sep | Aug | July | June | May | April | Mar | Feb | Jan | 11: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 10: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan |  | 09: Dec | Nov | Oct | Sep | Aug | Jl | Jn | May | Apr | Mar | Fb | Jn |  | 2008 | 2007 |

Drug, bio-affecting and body treating compositions

Below are recently published patent applications awaiting approval from the USPTO. Recent week's RSS XML file available below.
Listing for abstract view: USPTO application #, Title, Abstract excerpt,Patent Agent. Listing format for list view: USPTO National Class full category number, title of the patent application.
  
07/10/2014 > 206 patent applications in 103 patent subcategories.

20140193329 - Anti-cd151 antibodies and their use in the treatment of cancer: The present invention relates to new antibodies capable of binding specifically to the human CD151 protein, especially monoclonal antibodies of murine origin, which are chimeric and humanised, and also to the amino acid and nucleic sequences coding for those antibodies. The invention also includes use of those antibodies as medicaments... Agent: Pierre Fabre Medicament

20140193330 - Compositions and methods for multimodal imaging: There is provided signal modifying compositions for medical imaging comprising a carrier and signal modifying agents specific for two or more imaging modalities. The compositions are characterized by retention efficiency, with respect of the signal modifying agents that enables prolonged contrast imaging without significant depletion of the signal modifying agent... Agent: University Health Network

20140193331 - Multifunctional infrared-emitting composites: Disclosed is a method of non-invasive infrared imaging, comprising (a) administering a composition containing infrared-emitting particles which contain rare earth elements that emit in the short-wavelength infrared (SWIR) spectrum, where the particles are encapsulated with a biocompatible matrix to form downconverting encapsulated particles; and (b) irradiating with infrared radiation, where... Agent: Rutgers, The State University Of New Jersey

20140193332 - Compositions and methods for the diagnosis and treatment of inflammatory bowel disorders: The present invention is directed to compositions of matter useful for the diagnosis and treatment of inflammatory bowel diseases in mammals and to methods of using those compositions of matter for the same.... Agent: Genentech, Inc.

20140193334 - Targeted delivery and prodrug designs for platinum-acridine anti-cancer compounds and methods thereof: Acridine containing cisplatin compounds have been disclosed that show greater efficacy against cancer than other cisplatin compounds. Methods of delivery of those more effective cisplatin compounds to the nucleus in cancer cells is disclosed using one or more amino acids, one or more sugars, one or more polymeric ethers, C1-6alkylene-phenyl-NH—C(O)—R15,... Agent:

20140193333 - Therapeutic and diagnostic target: The present invention provides methods and compositions for treatment, screening, diagnosis and prognosis of acute myeloid leukemia (AML), B-cell chronic lymphocytic leukemia, breast cancer, colorectal cancer, kidney cancer, head and neck cancer, lung cancer, ovarian cancer or pancreatic cancer, for monitoring the effectiveness of acute myeloid leukemia (AML), B-cell chronic... Agent: Oxford Biotherapeutics Ltd

20140193335 - Devices and methods for the treatment of cancer: The invention relates to the treatment of cancer. In particular the invention relates to an internal therapeutic product comprising: (i) an anti-cancer component selected from one or both of: a radionucleotide, a cytotoxic drug; and (ii) a silicon component selected from one or more of: resorbable silicon, biocompatible silicon, bioactive... Agent: Enigma Therapeutics Limited

20140193336 - Imaging protocols: e

20140193337 - 18f-saccharide-folates: The present invention is directed towards new 18F-folate radiopharmaceuticals, wherein the 18F isotope is linked via a prosthetic group, more specifically via a prosthetic group having a saccharide group, such as a cyclic mono- or oligosaccharide, preferably based on a pyranoside or furanoside, which is covalently linked to the glutamate... Agent: Merck & Cie

20140193338 - Compounds for use in imaging, diagnosing and/or treatment of diseases of the central nervous system: This invention relates to novel compounds suitable for labelling by 18F and the corresponding 18F labelled compounds themselves, 19F-fluorinated analogues thereof and their use as reference standards, methods of preparing such compounds, compositions comprising such compounds, kits comprising such compounds or compositions and uses of such compounds, compositions or kits... Agent: Piramal Imaging Sa

20140193339 - New family of analogues and nadp+ or nadph, their preparation and their application in therapeutics: A new family of analogues of NADP+ or NADPH, their preparation and their application in therapeutics.... Agent:

20140193344 - Imaging contrast agents and uses thereof: Provided are macrocyclic compounds having a macrocyclic core which has at least one macrocyclic donor and at least one pendant group which has at least one donor group. The macrocyclic compounds can be complexed to Fe(II) and Ni(II). The macrocyclic compounds can be used in imaging methods. For example, the... Agent: The Research Foundation Of State University Of New York

20140193342 - Enzyme directed assembly of particle theranostics: Provided herein is a method for enzymatically triggered assembly of polymeric nanostructures for detection of cancer-associated enzymes in vivo. By detecting enzymatic signals associated with disease, one can sensitively determine the site, and extent of disease within a patient.... Agent: The Regents Of The University Of California

20140193341 - Human induced neuronal cells: A method for reprogramming a fibroblast into a human induced neuronal cell (hIN) is described. The method comprises expressing heterologous reprogramming factors Bm2, Myt11, Zic1, Olig2, Asc11 or any combination thereof, in said fibroblast, and culturing the fibroblast in a medium comprising BDNF, NT3, GeM or any combination thereof. Biomarkers... Agent:

20140193340 - Luciferin amides: m

20140193343 - Measurement of body fluid volumes: The present invention is related generally to measurement of body fluid volumes in an animal subject. The body fluid volumes of interest include extracellular fluid volume (ECFV), total vascular plasma volume (TVPV) and interstitial fluid volume (IFV). The methods are especially beneficial for subjects suffering from renal failure and particularly... Agent: Pharmacophotonics, Inc. D/b/a Fast Diagnostics

20140193345 - Herbal compositions for the treatment of mucosal lesions: The present invention provides therapeutic compositions comprising extracts of the plant species Echinacea purpurea and Sambucus nigra and the extract(s) of at least one further plant selected from the group consisting of Hypericum perforatum, Commiphora molmol and Centella asiatica. The compositions of the invention are of particular utility in the... Agent: Izun Pharmaceuticals Corporation

20140193346 - Health supplement: Herbal composition and method for the treatment of inflammatory pain associated with tendonitis, bursitis, arthritis, carpal tunnel syndrome, tennis elbow, plantar fasciitis, sports injuries, lower back pain and overexertion, gingivitis and muscle aches, that is compliant with HPUS monographs and/or over-the-counter FDA topical analgesic monograph requirements.... Agent: Drt Laboratories LLC

20140193347 - Lipid depot formulations: wherein at least one bioactive agent is dissolved or dispersed in the low viscosity mixture and wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with an aqueous fluid. The preformulations are suitable for generating parenteral, non-parenteral and topical depot compositions... Agent: Camurus Ab

20140193348 - Molecules, compositions, and methods for light absorption: Embodiments provided herein relate to molecules, compositions, and methods for light absorption. In some embodiments, the molecules and/or compositions can be used to absorb ultraviolet light. In some embodiments, the ultraviolet light absorption compound can be used in a sunscreen composition. In some embodiments, the compound includes an azobenzene group... Agent:

20140193350 - Agent containing microcapsules: The application relates to cosmetic agents, cleaning agents, and fabric treatment agents containing a combination of at least two different microcapsules as well as to methods for releasing active substances from said microcapsules when using said agents.... Agent: Henkel Ag & Co. Kgaa

20140193351 - Method and compositions for reducing pore size, and moisturizing and/or blurring appearance of defects on keratin surfaces: A method for simultaneously moisturizing and/or blurring the appearance of skin defects, or reducing pore size, or treating skin with a multi-benefit composition.... Agent:

20140193349 - Use of cannabinoid compounds for stimulating melanogenesis: it being understood that, when R3 and R4 together form an oxo group with the carbon atom which bears them and X represents an oxygen atom, then R1 cannot represent a hydroxymethyl group, as an agent for coloring keratin materials. It also relates to one of these specific cannabinoid compounds... Agent: L'oreal

20140193352 - Packaged product including a non-aerosol container and a shaving aid composition stored within: A packaged product and methods for manufacturing the same are provided. The packaged product includes a non-aerosol container and a shaving aid composition. The container includes a pocket. The shaving aid composition is in the form of a post-foaming gel and is stored within the pocket. The container is impermeable... Agent: Eveready Battery Company Inc.

20140193353 - Novel organopolysiloxane elastomer and use therefor: The present invention relates to an organopolysiloxane elastomer having a silicon-bonded sugar alcohol-modified group and having a crosslinked three-dimensional network structure comprising a carbon-silicon bond in the crosslinking portion. The organomodified organopolysiloxane elastomer of the present invention has, for example, affinity with various oil agents, has excellent viscosity-improving characteristics, gelification... Agent: Dow Corning Toray Co. Ltd.

20140193354 - Water-in-oil-in-water emulsions: The present invention generally relates to W/O/W emulsions including an oil-soluble polar modified polymer and polylysine.... Agent: L'oreal

20140193355 - Dermal protector: A denial protector liquid including a barrier and antimicrobial materials is disclosed. The protector liquid can be sprayed onto the skirt. The protector liquid can have a dispersant and moisturizer. When the base and solvents of the liquid evaporate, a polymer barrier and antimicrobial material can continue to reside on... Agent:

20140193356 - Compositions comprising citrate and applications thereof: In one aspect, methods of promoting bone growth are described herein. In some embodiments, a method of promoting bone growth described herein comprises promoting cell differentiation or phenotype progression in a population of bone cells by providing a citrate-presenting composition to the population of bone cells. In some embodiments, the... Agent: The Board Of Regents, The University Of Texas System

20140193357 - Derivatives of recombinant proteins, homo-multimers of granulocyte colony-stimulating factor and method of preparation thereof: The invention relates to derivatives of recombinant proteins, comprising homo-multimers of genetically fused recombinant biologically active protein monomer units, connected via selected peptide linker moiety; and the method of preparation thereof. Derivative of recombinant protein is preferably dimer of human granulocyte colony-stimulating factor, characterised by increased circulation time in vivo.... Agent:

20140193360 - Hydrogel comprising catechol group-coupled chitosan or polyamine and poloxamer comprising thiol group coupled to end thereof, preparation method thereof, and hemostat using same: The present invention relates to an adhesive hydrogel composition containing catechol group-coupled chitosan and Pluronic comprising a thiol group coupled to the end thereof, and more specifically, to an adhesive composition which is safe in vivo and in vitro, is temperature sensitive, and has an excellent hemostatic effect and thus... Agent: Innotherapy Inc.

20140193361 - Systemic glucose tolerance in type-2 diabetes: Obesity is associated with a state of chronic low-grade inflammation and the present invention establishes that adipose-resident natural killer T (NKT) cells attenuate inflammation in adipose tissue and improves systemic glucose homeostasis in mice at different stages of obesity. Accordingly, the present invention provides methods of treating type-2 diabetes or... Agent: Cornell University

20140193358 - Treating cancer stem cells using targeted cargo proteins: The disclosure provides targeted cargo proteins that are useful for targeting cancer stem cells, and methods of their use in treating cancer.... Agent: Protox Therapeutics, Inc.

20140193359 - Ultrafiltration concentration of allotype selected antibodies for small-volume administration: Disclosed are methods, compositions and uses of high concentration antibody or immunoglobulin formulations for subcutaneous, intramuscular, transdermal or other local (regional) administration, in a volume of than 3, less than 2 or less than 1 ml. Preferably, the formulation contains a high concentration formulation (HCF) buffer comprising phosphate, citrate, polysorbate... Agent: Immunomedics, Inc.

20140193363 - Novel benzimidazole derivatives: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a... Agent: Enanta Pharmaceuticals, Inc.

20140193362 - Yeast-based compositions and methods for the treatment or prevention of hepatitis delta virus infection: Disclosed are immunotherapeutic compositions and methods for preventing and/or treating hepatitis delta virus (HDV) infection, including yeast-based HDV immunotherapeutic compositions and methods of use of such compositions to prevent and/or treat HDV infection and symptoms and sequela thereof.... Agent: Globeimmune, Inc.

20140193364 - Tam receptor ligands, metabolites and precursors thereof in the detection and modulation of inflammatory neuropathological disease: The present disclosure relates to the use of TAM receptor ligands, metabolites, precursor and binding partners thereof in the field of inflammatory neuropathology. This includes the early diagnosis and monitoring of an inflammatory neuropathology as well as screening for medicaments used in the treatment and prophylaxis of such a condition.... Agent: Howard Florey Institute

20140193365 - Biodegradable drug delivery composition: The present disclosure provides a biodegradable drug delivery composition including a vehicle and an insoluble component comprising beneficial agent dispersed in the vehicle. Typically, the composition is not an emulsion, but has a low viscosity and further provides for minimized initial burst and sustained release of the beneficial agent over... Agent: Durect Corporation

20140193366 - Modulators of mir-323-3p for the prevention or treatment of rheumatoid arthritis: A miR-323-3p inhibitor is provided for the prevention or therapy of rheumatoid arthritis, comprising a sequence capable of forming a hybrid to miR-323-3p as an oligonucleotide or a vector from which such oligonucleotide is transcribed, or as a miRNA decoy or sponge.... Agent: Universitat Zurich Prorektorat Mnw

20140193382 - Endogenous expression of hla-g and/or hla-e by mesenchymal cells: Methods and compositions are provided for the identification and isolation of mammalian HLA-G+ MSC, HLA-E+ MSC, or HLA-G+/HLA-E+ MSC. The methods of the invention provide a means to obtain enriched HLA-G+ MSC, HLA-E+ MSC, or HLA-G+/HLA-E+ MSC populations.... Agent: Escape Therapeutics, Inc.

20140193367 - Method for reducing uremic toxins by probiotic composition and the manufacturing method thereof: The invention relates to a probiotic composition for reducing uremic toxins and the manufacturing method thereof. The probiotic composition comprises at least one selected from the group consisting of: Lactobacillus plantarum BCRC 12251, Lactobacillus paracasei BCRC 12188, Streptococcus thermophilus BCRC 13869 and pharmaceutically acceptable vehicles, excipients, diluents, adjuvants, etc. The... Agent: Conmed Pharmaceutical & Bio-medical Corporation

20140193368 - Pluripotent therapeutic compositions and uses thereof: Synthetic Stem Cell-like Tissue Healing and Regeneration Medication with Anti-inflammatory, Protein Synthesis, Enzyme Deficiency Activation and Genetic Therapy, and Anti-cancer Agent derived from a series of inventions that include these products of Biomolecular Engineering, Drug Discovery from a Biologic Periodic Table of Applied Biochemistry and Biophysics. Tissue has a self... Agent: Immunopath Profile, Inc.

20140193369 - Anti-inflammatory food product: According to some embodiments, a method selects one or more inflammatory markers to evaluate. The one or more inflammatory markers selected from the group consisting of iNOS, COX-2, TNF-alpha, NO, PGE2, IL-6, and IL-1β. The method determines a first expression level and a second expression level of the one or... Agent: Whitewave Services, Inc.

20140193371 - Method for the prevention and treatment of cancer, tuberculosis and related diseases: A method for preventing and treating one or more disease states including the steps of altering the diet of an individual and then administering a drug to the individual. Plasma vitamin C level is reduced from a first level to a second level that is lower than the first level,... Agent:

20140193370 - Methods and compositions for promoting lean body mass growth: The invention provides methods for promoting lean body mass growth in an animal. The methods comprise administering OEA to the animals, preferably in amounts of from about 0.01 to about 1000 mg/kg/day.... Agent: Nestec Sa

20140193372 - Reducing short-chain fatty acids and energy uptake in obese humans by managing their intestinal microbial communities: The present invention provides for microbial compositions and methods for reducing the concentration of short-chain fatty acids in the gut as a way to reduce energy uptake and manage obesity. More specifically, the invention provides for decreasing short-chain fatty acids available for absorption in the human gut, such as acetate,... Agent:

20140193384 - Use of lactobacillus for liver protection: A method for liver protection of a mammal is provided and includes administering an effective amount of isolated Lactobacillus plantarum CMU995 thereto. Providing a new use of Lactobacillus plantarum CMU995, which is deposited at the Food Industry Research and Development Institute (FIRDI) in Taiwan under accession number BCRC 910472 and... Agent: China Medical University

20140193383 - Use of lactobacillus kefiranofaciens as a probiotic and a synbiotic: In accordance with the present invention, there is provided a probiotic composition comprising an effective amount of Lactobacillus kefiranofaciens in association with a suitable carrier. The probiotic composition has many probiotic effects such as intestinal adherence, intestinal persistence, positive modulation of the intestinal microflora, protection against intestinal pathogens, immunomodulation, protection... Agent: Technologies Biolactis Inc.

20140193376 - Combined chemical modification of sphingosine-1-phosphate (s1p) and cxcr4 signalling pathways for hematopoietic stem cell (hsc) mobilization and engraftment: The present embodiments provide for combinations of modulators that increase hematopoietic stem cell engraftment or increase mobilization in vivo. Methods and compositions for modulating the mobilization of stem cells, particularly for promoting or increasing the mobilization of hematopoietic stem cells (HSCs) from the bone marrow to the peripheral blood are... Agent: Children's Medical Center Corporation

20140193381 - Fluid exchange methods and devices: Methods and devices for exchanging therapeutic agents, such as cells, from one liquid medium to another liquid medium are provided. Aspects of embodiments of the methods include transferring a therapeutic agent from a first medium, such as a freezing, storage or shipping buffer, into a second medium, such as a... Agent:

20140193378 - Ghrh agonists for islet cell transplantation and function and the treatment of diabetes: Disclosed herein are compositions of GHRH agonists and peptides, and methods to treat diabetes. In one embodiment, a method of promoting survival of grafted cells and/or tissues may involve exposing the cells and/or tissues to an effective amount of at least one agonist of GHRH. In some embodiments, the grafted... Agent: U.s.a., Represented By The Department Of Veterans Affairs

20140193375 - Mesenchymal stromal cell populations and methods of making same: The present invention provides compositions of mesenchymal stromal cells which express B7-H3, their subsequent use in tissue repair, improved methods of producing tissue repair cells and method of producing a substantially pure population of CD14+ autofluorescent macrophages.... Agent: Aastrom Biosciences, Inc.

20140193374 - Methods and compositions for culturing cells: The invention provides, among other things, methods and compositions for expanding stem cells. The invention further provides methods, devices and systems for directing differentiation of expanded stem cells. The invention further provides methods, devices and systems for treating a subject with differentiated cells in a subject in need thereof.... Agent: Arteriocyte Inc.

20140193373 - Methods for establishing and improving the survival of a population of pancreatic progenitor or stem cells: In some embodiments, methods for improving the survival of pancreatic β-cell progenitors in culture are provided. Such methods may include contacting a population of pancreatic progenitor cells with an amino acid (aa) sequence comprising IKVAV (SEQ ID NO:1). In other embodiments, methods for (i) verifying the establishment of a population... Agent:

20140193377 - Preparation of parental cell bank from foetal tissue: The present invention relates to methods of in vitro preparation of a parental cell bank (PCB) from foetal tissue consisting of foetal epiphyseal tissue, foetal Achilles tendon tissue and foetal skin tissue, using a rapid mechanical primary cell culture selection of cell type to be used in methods for wound... Agent: Centre Hospitalier Universitaire Voudois (chuv)

20140193380 - Technologies, methods, and products of small molecule directed tissue and organ regeneration from human pluripotent stem cells: Pluripotent human embryonic stem cells (hESCs) hold great potential for restoring tissue and organ function, which has been hindered by inefficiency and instability of generating desired cell types through multi-lineage differentiation. This instant invention is based on the discovery that pluripotent hESCs maintained under defined culture conditions can be uniformly... Agent: San Diego Regenerative Medicine Institute

20140193379 - Treatment of vasculopathy with prostacyclin and mesenchymal stem cells: Provided are methods for treating or preventing vasculopathy in a subject in need thereof, comprising administering to the subject a prostacyclin and a mesenchymal stem cell (MSC) or a MSC-conditioned culture medium or administering to the subject a MSC or a MSC-conditioned culture medium that has treated with prostacyclin. Pharmaceutical... Agent: United Therapeutics Corporation

20140193385 - Method for stimulating a host immune system: A method of manipulating allogeneic cells for use in allogeneic cell therapy protocols is described. The method provides a composition of highly activated allogeneic T-cells which are infused into immunocompetent cancer patients to elicit a novel anti-tumor immune mechanism called the “Mirror Effect”. In contrast to current allogeneic cell therapy... Agent: Immunovative Therapies, Ltd.

20140193386 - Method for enzymatic cross-linking of a protein: A method for cross-linking albumin for use as a sealant or glue for a biological system, for example to induce hemostasis and/or prevent leakage of any other fluid from a biological tube or tissue, such as lymph for example. The cross-linked albumin may optionally and preferably be applied as part... Agent: Lifebond Ltd.

20140193387 - Methods of reducing extravasation of inflammatory cells: A method for modifying access of cells to extravascular spaces and regions comprising administering to a patient an enzyme that cleaves chondroitin sulfate proteoglycans is provided. It has been found that administration of an enzyme that cleaves chondroitin sulfate proteoglycans to a patient disrupts extravasation of cells from the blood... Agent: Acorda Therapeutics, Inc.

20140193389 - Method for treating oncological diseases: A method to treat cancer and other malignant diseases, said method comprising parenterally administering an agent which destroys blood extracellular DNA into the systemic circulation of a cancer patient to slow down cancer growth. The agent is embodied in the form of a DNase enzyme and, more particularly, as a... Agent: Cls Therapeutics Limited

20140193388 - Modified phosphatases: The invention relates to phosphatases and more in specific to (genetically) modified phosphatases, pharmaceutical compositions comprising (genetically) modified phosphatases and the use of (genetically) modified phosphatases for treating or curing for example sepsis, inflammatory bowel disease or other inflammatory diseases, or renal failure. The invention further relates to a method... Agent: Am-pharma B.v.

20140193390 - High concentration alpha-glucosidase compositions for the treatment of pompe disease: The present application provides for compositions comprising high concentrations of acid α-glucosidase in combination with an active site-specific chaperone for the acid α-glucosidase, and methods for treating Pompe disease in a subject in need thereof, that includes a method of administering to the subject such compositions. The present application also... Agent:

20140193391 - Method and compositions for improving selective catabolysis and viability in cells of keratin surfaces: A composition for treating keratin surfaces to stimulate selective catabolysis and improve cellular viability comprising at least one autophagy activator and at least one DNA repair enzyme, and a method for improving selective catabolysis and cellular viability by treating with the composition.... Agent:

20140193392 - Methods and compositions to detect the level of lysosomal exocytosis activity and methods of use: Methods are provided for the prognosis, diagnosis and treatment of various pathological states, including cancer, chemotherapy resistance and dementia associated with Alzheimer's disease. The methods provided herein are based on the discovery that various proteins with a high level of sialylation are shown herein to be associated with disease states,... Agent: St. Jude Children's Research Hospital

20140193393 - Methods for treatment of stroke or cerebrovascular accidents using an etb receptor agonist: Methods of using an ETB receptor agonist, such as IRL-1620, for the treatment of stroke or cerebrovascular accidents are disclosed. The ETB receptor agonist is used alone or in combination with a second agent useful in the treatment of stroke or other cerebrovascular accident.... Agent: Midwestern University

20140193394 - Treatment of carpal tunnel syndrome by injection of the flexor retinaculum: An apparatus and method for identifying the flexor retinaculum of the carpal tunnel, injecting an effective amount of an agent into at least a portion of flexor retinaculum or tissue adjacent thereto, wherein the agent is configured to weaken the flexor retinaculum. The system may further include means for increasing... Agent: John M. Agee, Trustee Of The John M. Agee Trust Of August 15, 1996

20140193396 - Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response: The invention provides immune regulatory oligonucleotides (IRO) as antagonist of TLRs and methods of use thereof. These IROs have unique sequences that inhibit TLR-mediated signaling in response to a TLR ligand or TLR agonist. The methods may have use in the prevention and treatment of cancer, an autoimmune disorder, airway... Agent: Idera Pharmaceuticals, Inc.

20140193395 - Secretory iga compositions, methods of making and methods of use thereof: Described herein is secretory IgA isolated from the intestinal luminal fluid and intestinal mucosal of animals such as pigs and cows. Also included are methods of isolating secretory IgA. The secretory IgA is useful in food compositions such as animal and human food compositions as well as pharmaceutical compositions to... Agent: Wisconsin Alumni Research Foundation

20140193399 - Anti-cd3 antibodies and methods of use thereof: The present invention is related to antibodies directed to the antigen CD3 and uses of such antibodies. In particular, the present invention provides fully human monoclonal antibodies directed to CD3. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy... Agent:

20140193402 - Anti-pdgfr-beta antibodies and uses thereof: The present invention provides antibodies that bind to platelet derived growth factor receptor beta (PDGFR-beta) and methods of using the same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human PDGFR-beta with high affinity. The antibodies of the invention are useful for... Agent: Regeneron Pharmaceuticals, Inc.

20140193403 - Epitopes of il-17a and il-17f and antibodies specific thereto: The present invention relates neutralising epitopes of IL-17A and IL-17F and antibodies which bind those epitopes. The present invention also relates to the therapeutic uses of the antibody molecules and methods for producing them.... Agent: Ucb Pharma S.a.

20140193404 - Glycosylated antibodies: The invention provides an antibody comprising human IgG1 or IgG3 heavy chain constant domains that are glycosylated with a sugar chain at Asn297, said antibody being characterized in that the amount of fucose within said sugar chain is at least 99%, and in addition the amount of NGNA is 1%... Agent: Hoffmann-la Roche Inc.

20140193405 - Humanized anti-cd40 antibodies: Provided are humanized anti-CD40 antibodies and antigen-binding fragments and methods for treating disease characterized by expression of CD40 antigen.... Agent: Genentech, Inc.

20140193397 - Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy: The invention provides methods for identifying patient who may benefit from treatment with an anti-cancer therapy comprising a VEGF antagonist. The invention also provides methods for monitoring a patients' response to the anti-cancer therapy. The invention also provides kits and articles of manufacture for use in the methods.... Agent: Hoffmann-la Roche Inc.

20140193406 - Methods used in identifying glioblastoma: The invention encompasses methods and kits used in the identification of invasive glioblastoma based upon the expression of Akt1, Akt2, and Akt3. The methods and kits also allow prediction of disease outcome and staging of patients with regard to therapy.... Agent: Translational Genomics Research Institute

20140193401 - Pertussis antibodies and uses thereof: Compositions and methods are provided that are useful to treat respiratory diseases such as whooping cough. Further, compositions and methods of immunizing are provided.... Agent: Board Of Regents, The University Of Texas System

20140193398 - Polymalic acid-based nanobiopolymer compositions: Nanobiopolymeric conjugates based on biodegradable, non-toxic and non-immunogenic poly (β-L-malic acid) PMLA covalently linked to molecular modules that include morpholino antisense oligonucleotides (AONa), an siRNA or an antibody specific for an oncogenic protein in a cancer cell, and an antibody specific for a transferrin receptor protein, are provided. Methods for... Agent:

20140193400 - Stable and soluble antibodies inhibiting tnf alpha: The present invention relates to particularly stable and soluble scFv antibodies and Fab fragments specific for TNF, which comprise specific light chain and heavy chain sequences that are optimized for stability, solubility, in vitro and in vivo binding of TNF, and low immunogenicity. Said antibodies are designed for the diagnosis... Agent: Esba Tech, An Alcon Biomedical Research Unit LLC

20140193410 - Compositions and methods for the regulation of t regulatory cells using tl1a-ig fusion protein: Compositions comprising TL1A-Ig fusion proteins and methods of their use, e.g., for the treatment of diseases and disorders associated with antigen-specific immune responses, are described. Also described are combination therapies that include the administration of a TNFRSF25 agonist and an interleukin (e.g., IL-2) and/or an mTOR inhibitor (e.g., rapamycin).... Agent: University Of Miami

20140193407 - Drug fusions and conjugates: The present invention relates to drug fusions that have improved serum half lives. These fusions and conjugates comprise polypeptides, immunoglobulin (antibody) single variable domains and GLP and/or exendin molecules. The invention further relates to uses, formulations, compositions and devices comprising such drug fusions and conjugates.... Agent: Glaxo Group Limited

20140193409 - Fusion proteins for delivery of gdnf to the cns: The invention provides compositions, methods, and kits for increasing transport of GDNF across the blood brain barrier while allowing its activity to remain substantially intact. The GDNF is transported across the blood brain barrier via one or more endogenous receptor-mediated transport systems.... Agent: Armagen Technologies, Inc.

20140193411 - Multimeric constructs: Multimeric fusion proteins of an Ig-like domain of Flt-1 are rendered functional by inclusion of a linker moiety. Vectors encoding the fusion proteins and host cells expressing the fusion proteins can be used therapeutically to block neovascularization in individuals with pathological conditions related to neovascularization. Such conditions include age-related macular... Agent: Genzyme Corporation

20140193408 - Soluble proteins for use as therapeutics: The present invention relates to improved binding proteins, for use as a medicament, in particular for the prevention or treatment of autoimmune and inflammatory disorders, for example allergic asthma and inflammatory bowel diseases. The invention more specifically relates to a soluble protein, comprising a complex of two heterodimers, wherein each... Agent: Novartis Ag

20140193413 - Antibodies binding to phosphorylcholine (pc) and/or pc conjugates: The present disclosure relates to an antibody or antibody fragment capable of binding to phosphorylcholine and/or a phosphorylcholine conjugate, wherein the antibody or antibody fragment comprises a variable heavy chain (VH) domain and/or a variable light chain (VL) domain, and wherein (a) the VH domain comprises complementarity determining regions (CDRs)... Agent: Athera Biotechnologies Ab

20140193412 - Treatment of cutaneous wounds by inhibiting cold shock proteins: Disclosed are methods of treating a subject suffering from a cutaneous wound comprising administering to the subject a CIRP inhibitor.... Agent: The Feinstein Institute For Medical Research

20140193414 - Anti-her antibodies: The invention provides anti-HER antibodies, including multispecific anti-HER antibodies, compositions comprising and methods of using these antibodies. Also provided herein are EGFR/HER3 multispecific antibodies that are less toxic than traditional EGFR antagonists.... Agent: Genentech, Inc.

20140193415 - Bispecific anti-egfr/anti igf-1r antibodies: The present invention relates to bispecific anti-EGFR/anti IGF-1R antibodies, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.... Agent: Roche Glycart Ag

20140193416 - Oligosaccharides and oligosaccharide-protein conjugates derived from clostridium difficle polysaccaride ps-i, methods of synthesis and uses thereof, in particular as vaccines and diagnostic tools: The invention relates to a synthetic oligosaccharide representing part of the repeating unit of the Clostridium difficile glycopolymer PS-I and having the sequence of the pentasaccharide a-L-Rhap-(1→3)-β-D-Glcp-(1→4)-[a-L-Rhap-(1→3]-a-D-Glcp-(1→2)-a-D-Glcp or a synthetic fragment or derivative thereof. Preferably, the claimed synthetic oligosaccharide bears at least one linker L for conjugation to a carrier... Agent: Max-planck-gesellschaft Zur Foerderung Der Wissenschaften E.v.

20140193418 - Anti-human epo receptor antibodies and methods of use: Herein is reported an antibody that specifically binds to human EPO receptor, wherein the antibody binds to EPO receptor fragment LPGPGGSVDIV (SEQ ID NO: 01) but that does not specifically bind to a protein obtainable from human endothelial cells that has a molecular weight of about 66 kD.... Agent: Hoffmann-la Roche Inc.

20140193421 - Anti-human xcr1 antibodies: An object of the present invention is to provide a monoclonal antibody binding to human XCR1, wherein the antibody binds to linear or discontinuous epitopes which comprise at least three amino acids selected from the group consisting of the 8th, 11th, 12th, 13th, 14th, 16th, 17th, 22nd, 23rd, 176th, and... Agent: Eisai R&d Management Co., Ltd.

20140193420 - Diagnosis and treatment of cancer using anti-itm2a antibody: Disclosed is a monoclonal antibody binding to an ITM2A protein. This antibody is useful in the diagnosis, prevention, and treatment of cancer such as Ewing's sarcoma, T cell leukemia, T cell lymphoma, acute myeloid leukemia, B cell tumor, and multiple myeloma. The present invention also provides a pharmaceutical composition, a... Agent: The University Of Tokyo

20140193417 - Membrane transporter napi2b (scl34a2) epitope for antibody therapy, antibodies directed thereto, and target for cancer therapy: The present disclosure relates generally to the membrane transporter NaPi2b (SLC34A2) as a target for therapy, including immunotherapy, and particularly cancer therapy. The SLC34A2 epitope peptide encompassing amino acids 312-340 of SLC34A2 has been identified as an ovarian cancer epitope using the monoclonal antibody MX35. The invention also relates to... Agent: Institute For Molecular Biology

20140193419 - Methods and compositions for treating and diagnosing diseases: Methods and compositions for diagnosing and treating diseases, particularly cancer, associated with differential expression of cancer-associated targets (CAT) in disease cells compared to healthy cells are provided. Also provided are antagonists and agonists of CAT, and methods for screening agents that modulate CAT level or activity in vivo or in... Agent: Celera Corporation

20140193422 - Fully human antibodies against human 4-1bb: Fully human antibodies and antigen-binding portions thereof that bind to human 4-1BB and that allow binding of human 4-1BB to a human 4-1BB ligand. In one aspect, the antibody is an IgG4 antibody. Also provided is a method for treating a disease in a subject comprising administering a therapeutically effective... Agent:

20140193427 - Anti-gdf15 antibodies: Monoclonal antibodies that bind and inhibit the activity of human GDF15 are disclosed. The antibodies can be used to treat body weight loss, including cachexia, associated with the over-expression of human GDF15.... Agent: Aveo Pharmaceuticals, Inc.

20140193423 - Diagnosis and treatment of viral diseases: This disclosure relates to methods of diagnosing a viral disease in a patient by identifying one or more virus-specific elements or a patient antibody to a virus-specific element, as well as to kits for diagnosing a viral disease in a patient. The disclosure further relates to methods of monitoring disease... Agent:

20140193426 - Markers for early diagnosis of ovarian cancer, monitoring during therapy, and new therapy options during and after chemotherapy: The inventors have identified several proteases and a protease inhibitor that are overexpressed in ovarian cancer tumors. They have developed monoclonal antibodies against the proteins and shown that they can be detected in serum and the levels of the proteins in serum fluctuate during cancer treatment. They have shown that... Agent: The Board Of Trustees Of The University Of Arkansas

20140193424 - Method and medicament for inhibiting lymphangiogenesis: The present invention provides a method for inhibiting lymphangiogenesis in a subject, comprising administering a therapeutically effective amount of a CXCR4 inhibitor and/or a CXCL12 inhibitor to the subject. The invention further provides a method for inhibiting tumor lymphatic metastasis in a cancer patient, comprising administering to the subject (a)... Agent:

20140193425 - Treatment of cancer with alk1 antagonists: Methods for evaluating responsiveness of a subject having cancer to treatment with an activin receptor-like kinase 1 (ALK1) antagonist are provided. Methods for selecting a subject for treatment with an ALK1 antagonist based on the subject being identified as responsive to such treatment are also provided. Some of the diagnostic... Agent: Acceleron Pharma, Inc.

20140193428 - Human cytomegalovirus neutralizing antibodies and use thereof: The invention relates to neutralizing antibodies, and antibody fragments thereof, having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for one, or a combination of two or more, hCMV gene UL products. The invention also relates to immortalized B cells that produce, and to epitopes... Agent: Institute For Research In Biomedicine

20140193429 - Metal-citrate transporter antigen from streptomyces coelicolor and uses thereof: The present invention relates to an isolated antigen from Streptomyces coelicolor that is useful for developing, inter alia, vaccines against pathogenic bacteria of humans and animals. The present invention also relates to vaccines and antibodies developed using the isolated antigen. The present invention also relates to methods of using the... Agent: Syracuse University

20140193431 - Anti-c-met antibody having hgf activity and use thereof: Disclosed are a human antibody comprising a human complementarity-determining region (CDR), which binds specifically to c-Met, and a framework region (FR), a polynucleotide encoding the human antibody, an expression vector comprising the polynucleotide, a transformant transformed with the expression vector, a method of producing the human antibody B7 by culturing... Agent: Korea Research Institute Of Bioscience And Biotechnology

20140193430 - Compositions and methods for regulating nk cell activity: The present invention relates to novel compositions and methods for regulating an immune response in a subject. More particularly, the invention relates to specific antibodies that regulate the activity of NK cells and allow a potentiation of NK cell cytotoxicity in mammalian subjects. The invention also relates to fragments and... Agent: Bristol-myers Squibb Company

20140193432 - Anti-hdlk-1 antibody having an antitumor activity in vivo: The present invention provides: antibodies specifically reacting against hDlk-1 and having anti-tumor activity in vivo (anti-hDlk-1 antibodies, and in particular, humanized anti-hDlk-1 antibodies); fragments of the antibodies; hybridomas that produce the antibodies; a complex of the antibody or antibody fragment and an agent; a pharmaceutical composition, a tumor therapeutic agent,... Agent: Livtech, Inc.

20140193433 - Bcma-based stratification and therapy for multiple myeloma patients: The present invention relates to methods for the stratification of a multiple myeloma (MM) patient comprising determining whether or not B-cells, preferably malignant B-cells of said patient express BCMA protein on their surface. Also, methods for selecting an antibody-based multiple myeloma (MM) therapy is based on whether or not BCMA... Agent: Boehringer Ingelheim International Gmbh

20140193434 - Pharmaceutical composition for treatment and/or prophylaxis of cancer: It is intended to identify a cancer antigenic protein specifically expressed on the surface of cancer cells and to provide an antibody targeting the antigenic protein and use of the antibody as a therapeutic and/or preventive agent for cancer. The present invention provides an antibody or a fragment thereof which... Agent: Toray Industries, Inc.

20140193436 - Extracellular targeted drug conjugates: Extracellular-targeted drug conjugates (EDC) in which a targeting moiety targeting a protein associated with the Na,K-ATPase is linked to a drug that interacts with the Na,K-ATPase through a linker a stable linker are useful in the treatment of disease and as tools for the evaluation of biological systems.... Agent: Centrose, LLC

20140193435 - Method for integrating large scale biological data with imaging: There is disclosed a method of extracting large scale biological, biochemical or molecular information about an index disease, biological state, or systems from imaging by correlating the imaging features associated with said disease, state or system with corresponding large scale biological data.... Agent: Algeomics, LLC

20140193438 - Enediyne compounds, conjugates thereof, and uses and methods therefor: Enediyne compounds having a structure according to formula (I), where R0, R2, R3, R4, R5, R6, and R7 are defined herein, can be used in chemotherapeutic drugs, especially in conjugates, for the treatment of diseases such as cancer.... Agent: Bristol-myers Squibb Company

20140193437 - Hydrophilic self-immolative linkers and conjugates thereof: The present disclosure provides compounds with a hydrophilic self-immolative linker, which is cleavable under appropriate conditions and incorporates a hydrophilic group to provide better solubility of the compound. The compounds of the present disclosure comprise a drug moiety, a targeting moiety capable of targeting a selected cell population, and a... Agent: Abgenomics International Inc.

20140193440 - Markers of alzheimers disease: An inflammatory process is suggested to be involved in the pathogenesis of Alzheimer's disease (AD), a neurodegenerative disorder characterized by the presence of neuritic plaques within the cerebral cortex that are mainly composed of a small insoluble protein of 40-42 aminoacids (amyloid protein). Amyloid-specific Interleukin-10 (IL-10) generation is found to... Agent:

20140193439 - Vaccines and immunotherapeutics comprising il-15 receptor alpha and/or nucleic acid molecules encoding the same, and methods for using the same: Compositions, recombinant vaccines and live alternated pathogens comprising one or more isolated nucleic acid molecules that encode an immunogen in combination with an isolated nucleic acid molecule that encodes IL-15Ra or a functional fragment thereof are disclosed. Methods of inducing an immune response in an individual against an immunogen, using... Agent:

20140193444 - Allergen peptide fragments and use thereof for treatment of dust mite allergies: The present invention relates generally to in vivo methods and compositions designed for allergen specific immunotherapy. The compositions include contiguous overlapping peptide fragments which together form an entire amino acid sequence of an allergen.... Agent: Anergis S.a.

20140193441 - Method of administering porcine b-domainless fviii: The present invention provides a method of administering porcine B-domainless factor VIII (OBI-1) to a patient having factor VIII deficiency to provide more rapid and effective protection against bleeding episodes, compared to formerly available methods, or to provide more effective protection to such patients during non-bleeding periods. This invention is... Agent:

20140193442 - Method of treating cancer with an hla-a*3303-restricted wt1 peptide and pharmaceutical composition comprising the same: Disclosed are: a peptide comprising an amino acid sequence composed of contiguous nine amino acid residues derived from a WT1 protein, wherein an amino acid residue at position 2 in the amino acid sequence is selected from the group consisting of Ala, Ile, Leu, Val, Phe, Tyr, Ser and Asp... Agent: International Institute Of Cancer Immunology, Inc.

20140193443 - Method of treating cancer with an hla-a*3303-restricted wt1 peptide and pharmaceutical composition comprising the same: Disclosed are: a peptide comprising an amino acid sequence composed of contiguous nine amino acid residues derived from a WT1 protein, wherein an amino acid residue at position 2 in the amino acid sequence is selected from the group consisting of Ala, Ile, Leu, Val, Phe, Tyr, Ser and Asp... Agent: International Institute Of Cancer Immunology, Inc.

20140193445 - Truncated secretory aspartyl proteinase 2: The present invention relates to an isolated truncated form of the secretory aspartyl proteinase 2, as well as to nucleic acid molecules encoding same. The present invention also relates to a composition comprising an isolated truncated form of the secretory aspartyl proteinase 2, as well as to nucleic acid molecules... Agent: Pevion Biotech Ltd.

20140193446 - Biodegradable high-efficiency dengue vaccine, method for making the same, and pharmaceutical composition comprising the same: The present invention is related to a biodegradable high-efficiency dengue vaccine, a method for making the same, and a pharmaceutical composition comprising the same. The biodegradable high-efficiency dengue vaccine comprises a biodegradable nanocomplex with electric properties holding a dengue viral protein inside. An organism has antibody responses after vaccination with... Agent:

20140193447 - Functional influenza virus-like particles (vlps): The present invention discloses and claims virus like particles (VLPs) that express and/or contains seasonal influenza virus proteins, avian influenza virus proteins and/or influenza virus proteins from viruses with pandemic potential. The invention includes vector constructs comprising said proteins, cells comprising said constructs, formulations and vaccines comprising VLPs of the... Agent: Novavax, Inc.

20140193448 - Vaccine against multitypes of avian influenza viruses and uses thereof: The present invention relates to a recombinant DNA molecule encoding a mutated hemagglutinin protein, wherein the mutated hemagglutinin protein consists of the amino acid sequence of SEQ ID NO: 2 with one or more mutations at amino acid residue selecting from the group consisting of residue 83, 127, 138 and... Agent: National Tsing Hua University

20140193449 - Compositions and methods for cancer treatment: Compositions and methods for delivering tumor associated antigens and immune modulatory molecules to result in a therapeutic effect are disclosed. The compositions and methods use stably integrating lentiviral delivery systems. The methods are useful for therapeutically and prophylactically treating cancer such as colon cancer.... Agent: University Health Network

20140193450 - Peptide carrier fusion proteins as allergy vaccines: The present invention relates to a polypeptide comprising at least three peptide fragments consisting of 10 to 50 consecutive amino acid residues of at least one wild-type allergen fused to the N- and C-terminus of a surface polypeptide of a virus of the hepadnaviridae family or at least one fragment... Agent: Biomay Ag

20140193451 - Immunogenic composition: The present invention relates to immunogenic compositions comprising 26 μg-45 μg of pneumolysin and/or PhtD, vaccines comprising the immunogenic compositions and their use in medicine.... Agent: Glaxosmithkline Biologicals Sa

20140193452 - Novel agents for the prevention of leishmaniasis: The invention relates to nucleic acid constructions, characterized in that they comprise nucleic acids which are isolated in the sense position and which are capable of coding for an immunogenic protein of promastigotes or amastigotes of Leishmania, said nucleic acids responding to one of the sequences SEQ ID NO:1, SEQ... Agent:

20140193453 - Immunomodulatory agent-polymeric compounds: This invention relates to compositions, and related compounds and methods, of conjugates of immunomodulatory agents and polymers or unit(s) thereof. The conjugates may be contained within synthetic nanocarriers, and the immunomodulatory agents may be released from the synthetic nanocarriers in a pH sensitive manner.... Agent: Selecta Biosciences, Inc.

20140193456 - Method for drying-conservation of natural substances: The invention comprises of an implementation of the lyophilization process in a method for a large-scale preservation of the entire biological material prior to the extraction and/or the utilization/manipulation of any substances of the biological content. The drying-conservation of all the natural substances is achieved via deep-freezing evaporation followed by... Agent:

20140193454 - Method from preparing ceriporia lacerata culture extract and pharmaceutical composition for prevention or treatment of diabetes and diabetic complications comprising ceriporia lacerata culture extract as active ingredient: A method for preparing a Ceriporia lacerata mycelium culture extract and a pharmaceutical composition for preventing or treating diabetes and diabetic complications, contains a Ceriporia lacerata mycelium culture extract prepared by the above method. The Ceriporia lacerata mycelium culture extract prepared according to the preparation method of the invention has... Agent:

20140193455 - Pharmaceutical composition for prevention or treatment of steroid-induced diabetes and health functional food: A pharmaceutical composition for preventing or treating steroid-induced diabetes (SID) and a health functional food, and more particularly to a pharmaceutical composition for preventing or treating SID and a health functional food, contain a Ceriporia lacerata culture extract as an active ingredient. The pharmaceutical composition and the health functional composition... Agent:

20140193457 - Immunostimulatory oligodeoxynucleotides: The present invention relates to immunostimulatory oligodeoxynucleotides, vectors and vaccines comprising such oligodeoxynucleotides, to their use as a medicament, to their use in preventing or combating infectious disease and to methods for the detection of such oligodeoxynucleotides.... Agent:

20140193458 - Method of vaccination comprising a histone deacetylase inhibitor: A vaccination method is provided. The method comprises administering to a mammal a histone deacytelase inhibitor in conjunction with a vaccine that expresses an antigen to which the mammal has a pre-existing immunity.... Agent:

20140193459 - Vaccine composition containing synthetic adjuvant: Compositions and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed based on the discovery of useful immunological adjuvant properties in a synthetic, glucopyranosyl lipid adjuvant (GLA) that is provided in substantially homogeneous form. Chemically defined, synthetic GLA offers a consistent vaccine component from... Agent: Infectious Disease Research Institute

20140193460 - Herpes virus vaccine and methods of use: Provided herein are, inter alia, vaccines and methods of using the same for the treatment or prevention of Herpesvirus infections.... Agent: The Regents Of The University Of California

20140193461 - Streptococcus vaccine compositions and methods of using the same: The present invention provides methods and compositions for the stimulation of immune responses. In particular, the present invention provides immunogenic nanoemulsion compositions and methods of using the same for the induction of immune responses (e.g., innate and/or adaptive immune responses (e.g., for generation of host immunity against a bacterial species... Agent: The Regents Of The University Of Michigan

20140193462 - Methods for cancer treatment using stem cells: Various embodiments of the invention provide methods of treating cancer. Many embodiments provide methods of treating cancer using stem cells. In one embodiment the method comprises removing cancer cells from a patient and culturing the cancer cells in the presence of stem cells under conditions such that the stem cells... Agent: Incube Labs Inc.

20140193467 - Compositions comprising tnf-specific antibodies for oral delivery: In accordance with the invention, the development and use of antibodies within the digestive tract is provided. Antibodies are described that are used to treat disorders associated with altered permeability of the digestive tract. Antibodies are described with increased stability within the environment of the digestive tract. Antibodies are described... Agent: Avaxia Biologics, Incorporated

20140193464 - Effects of probiotics on humans and animals under environmental or biological changes: A dry, stable and viable probiotic composition comprising, a probiotic microorganism and a dried plant powder, with the proviso that said composition is not a blended mixture of at least one biologically pure Pediococcus acidilactici probiotic culture and dried tomato powder at a weight ratio of 1:4 encapsulated in an... Agent: Imagilin Technology, LLC

20140193468 - Methods for preparation of neo-cartilage constructs: The invention generally relates to systems (i.e. constructs) for repairing cartilage and methods for preparing the same that introduce a bioactive agent into a culture medium, suspension, scaffold, solution incorporated into the pores of the scaffold, or combinations thereof. The introduction of a bioactive agent promotes production of neo-cartilage (i.e.... Agent: Histogenics Corporation

20140193465 - Novel a4b7 peptide dimer antagonists: The invention relates to disulfide-rich dimer molecules which inhibit binding of α4β7 to the mucosal addressin cell adhesion molecule (MAdCAM) in vivo, and show high selectivity against α4β1 binding.... Agent: Protagonist Therapeutics, Inc.

20140193463 - Peptide for inhibiting dipeptidyl-peptidase iv: A method for inhibiting dipeptidyl-peptidase IV is provided and includes administering a peptide to the dipeptidyl-peptidase IV, in which the peptide is isolated from a gelatin hydrolysate produced by enzymatic digestion with alcalase (ALA), bromelain (BRO), and flavourzyme (FLA).... Agent: China Medical University

20140193466 - Silk compositions and methods of using same: The present invention provides for silk-derived compositions for treating a wide variety of ocular conditions. The composition is produced by processing the silk cocoon into a water-based solution (i.e., a dissolved silk), which is then cast into a film. The film may be transparent to visible light, and curved in... Agent: Cornell University

20140193469 - Aqueous compositions comprising polymer particles and low levels of clay: The present invention features a composition that includes about 0.75% to about 1.25% by weight of a clay portion that comprises bentonite. The composition includes polymer particles having an average particle size of less than about 20 microns and a refractive index of about 1.3 to about 1.4. The composition... Agent:

20140193470 - Cosmetic method for treating human perspiration using particles of an expanded amorphous mineral material; compositions: Provided is a cosmetic method for treating perspiration and, optionally, the body odors related to thereto, e.g. underarm odors, with an effective amount of particles of an expanded amorphous mineral material or of a composition thereof, and more particularly containing expanded perlite particles. The composition can contain, in a cosmetically... Agent: L'oreal

20140193471 - Solid antiperspirant and/or deodorant composition in the form of a water-in-oil emulsion based on silicone emulsifiers and on waxes; method for treating body odours: The invention relates to a solid composition in the form of a water-in-oil emulsion comprising, in a cosmetically acceptable carrier: (i) at least one discontinuous aqueous phase, (ii) at least one fatty phase comprising at least one particular wax, (iii) at least one silicone emulsifier selected in the group consisting... Agent: L'oreal

20140193472 - Formulations for paddy rice fields: The present invention relates to microcapsules, formulations comprising such microcapsules and to methods of combating phytopathogenic pests in paddy rice fields based on such microcapsules.... Agent: Basf Se

20140193474 - Low particulate lubricious coating with vinyl pyrrolidone and acidic polymer-containing layers: Embodiments of the disclosure include lubricious coatings. In an embodiment the disclosure includes a lubricious coating for a medical device including first and second coated layers. The first coated layer is between the second coated layer and the device surface and includes a vinyl pyrrolidone polymer and a photo reactive... Agent:

20140193473 - Materials and methods for controlling vasculogenesis from endothelial colony forming cells: Materials and methods are disclosed for controlling vasculogenesis using building blocks of a collagen matrix and endothelial colony forming cells (ECFC). The building blocks may be isolated by fractionating an acid soluble Type I collagen. The building blocks comprising monomers and/or oligomers may be recombined in desired ratios to alter... Agent: Indiana University Research And Technology Corp.

20140193475 - Polymers comprising amorphous terpolymers and semicrystalline blocks: The present invention provides an implantable article comprising an amorphous terpolymer and a semi-crystalline polymer. The amorphous terpolymer can be admixed with the semi-crystalline polymer or form a block copolymer with the semi-crystalline polymer.... Agent: Abbott Cardiovascular Systems Inc.

20140193476 - Chitosan hydrogel derivatives as a coating agent with broad spectrum of antimicrobial activities: In order to achieve hydrogel formation, quaternized chitosan can be grafted with polymerizable groups, especially photocrosslinkable groups, such as methacrylates, PEG derivatives and be converted into hydrogels through a thermal or UV polymerization process. Hydrogels are hydrated cross-linked polymeric systems that contain water in an equilibrium state forming cushion water... Agent: Menicon Co., Ltd.

20140193477 - Collagen based materials and uses related thereto: This disclosure relates to materials fabricated from collagen and uses relates thereto. Typically, layers of collagen are stretched during a curing period and optionally coated or impregnated with an elastin like protein. In certain embodiments, these materials can be used in tissue repair or arranged into cylinders and utilized as... Agent: Beth Israel Deaconess Medical Center, Inc.

20140193479 - Compositions and methods for treatment of mammalian skin: Compositions useful for treatment of a wide range of skin disorders including: pre-cancerous lesions, keratotic lesions, superficial basal cell carcinomae; squamous cell carcinomae; malignant melanoma, and radiation-induced burns. In some embodiments the treatments comprise contacting human or other mammalian skin with a composition according to the disclosure. In other embodiments,... Agent: Berry Pharmaceuticals, L.L.C.

20140193478 - Compositions and methods for treatment on mammalian skin: Compositions useful for treatment of a wide range of skin disorders including: pre-cancerous lesions, keratotic lesions, superficial basal cell carcinomae; squamous cell carcinomae; malignant melanoma, and radiation-induced burns. In some embodiments the treatments comprise contacting human or other mammalian skin with a composition according to the disclosure. In other embodiments,... Agent: Berry Pharmaceuticals, L.L.C.

20140193484 - Influenza virus immunogenic compositions and uses thereof: Immunogenic compositions comprise a RNA component and a polypeptide component. The RNA component is a self-replicating RNA. The polypeptide component comprises an epitope from an influenza virus antigen (the first epitope), and the RNA component encodes a polypeptide which also comprises an epitope from an influenza virus antigen (the second... Agent:

20140193482 - Modified polynucleotides encoding v-myc avian myelocytomatosis viral oncogene homolog: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules.... Agent: Moderna Therapeutics, Inc.

20140193485 - Orally administrable liposomally encapsulated reduced glutathione, with ace inhibitors for reversal and prevention of oxidation of cholesterol and of low density lipoprotein: The invention proposes the combination of reduced glutathione in a liposome (liposomal reduced glutathione) with a specified concentration of reduced glutathione within the liposome for the oral administration of a therapeutically effective amount to ameliorate the progression of vascular disease, including atherosclerosis, diabetes, hypertension, narrowing of arteries leading to decreased... Agent: Your Energy Systems, LLC

20140193481 - Stabilised vaccine composition: e

20140193486 - Sustained releasing composition via local injection for treating eye diseases: The invention provides a sustained release composition for intravitreal injection to the eye of a subject in need thereof. The sustained release composition contains an effective amount of a therapeutic agent in association with a nanosphere. The nanosphere contains a particle that comprises a particle-forming component capable of forming a... Agent: Taiwan Liposome Company

20140193483 - Therapeutic vaccines for treating herpes simplex virus type-2 infections: The invention provides methods and kits for inducing a therapeutic immunity in animals (e.g. mammals) against viral antigens, including herpes-simplex virus type 2. In particular, the invention provides a method of treating animals with an established HSV-2 infection by administering a therapeutic vaccine comprising a priming dose of a nucleic... Agent: Biomedical Research Models, Inc.

20140193480 - Topical anti-inflammatory compositions and uses thereof: Disclosed are pharmaceutical compositions and topical formulations thereof that include multiple, phytochemically-active, nutraceutical compounds, and that possess potent anti-inflammatory and extracellular matrix-stabilizing properties both in vitro and in vivo. Also disclosed are prophylactic and therapeutic methods, as well as dosing regimens and medicaments for use in preventing chronic disease, for... Agent: Md Matrix Health LLC Dba Md Matrix Health Inc.

20140193487 - Compositions and methods for treating centrally mediated nausea and vomiting: Provided are compositions and methods for treating or preventing nausea and vomiting in patients undergoing chemotherapy, radiotherapy, or surgery.... Agent: Helsinn Healthcare S.a.

20140193489 - Dopamine nanocapsules and uses thereof: The present invention provides a sonochemical irradiation-based method for the preparation of polydopamine (PDA) nanocapsules having reduced wall thickness and uniform size distribution, which may further comprise at least one payload; nanocapsules obtained by this method; and compositions thereof. Such compositions may be formulated for different purposes, e.g., as pharmaceutical... Agent: Bar-ilan University

20140193488 - In situ antigen-generating cancer vaccine: The invention provides compositions and methods for utilizing scaffolds in cancer vaccines.... Agent: President And Fellows Of Harvard College

20140193490 - Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats: The present invention relates to oral dosage form with active agents in controlled release cores and in immediate release gelatin capsule coats.... Agent: Pain Therapeutics, Inc.

20140193492 - Method for the preparation of a pharmaceutical composition comprising 5-aminosalicylic acid for use in treatment of ulcerative colitis and crohn's disease: The present invention concerns a new method of preparing granules comprising 5-aminosalicylic acid and a new method of preparing a pharmaceutical composition for the treatment of ulcerative colitis or Crohn's disease by oral administration comprising as active ingredient 5-aminosalicylic acid.... Agent: Ferring B.v.

20140193491 - Pharmaceutical antiretroviral composition: The present invention relates to a pharmaceutical antiretroviral composition comprising (i) a nucleoside reverse-transcriptase inhibitor selected from lamivudine and emtricitabine, (ii) extended release nevirapine, and (iii) tenofovir; a process for preparing such composition and the use of such composition in medicine, particularly for the prophylaxis and/or treatment of diseases caused... Agent: Cipla Limited

20140193495 - Controlled release pharmaceutical compositions comprising a fumaric acid ester: The present invention relates to controlled release pharmaceutical compositions comprising fumaric acid ester(s) as active substance(s). The compositions are suitable for use in the treatment of e.g. psoriasis or other hyperproliferative, inflammatory or autoimmune disorders and are designated to release the fumaric acid ester in a controlled manner so that... Agent: Forward Pharma A/s

20140193496 - Intrabuccally rapidly disintegrating tablet and a production method of the tablets: An intrabuccally rapidly disintegrating tablet which is manufactured by a simple method, has an enough practical hardness and is rapidly disintegrated in the buccal cavity and its production method. The intrabuccally rapidly disintegrating tablet is produced by growing a powder material into a granulated material with a fixed particle diameter,... Agent: Kyowa Hakko Kogyo Co., Ltd.

20140193494 - Misuse preventative, controlled release formulation: Disclosed is a misuse preventative, controlled release formulation comprising a core comprising a superabsorbent material (for example, polycarbophil), a controlled release coat surrounding the core, and a plurality of controlled release microparticles having a pharmaceutically active agent (for example, an opioid analgesic) disposed within the core, the coat, or both... Agent: Paladin Labs (barbados) Inc.

20140193493 - Solid dosage forms of oleyl phosphocholine: The present invention relates to solid dosage forms of oleyl phosphocholine (C18:1-PC), or OlPC, for oral administration. Further, the present invention relates to methods for the preparation of the present solid dosage forms and the use thereof as a medicament and especially a medicament for treatment of parasitic diseases, such... Agent: Dafra Pharma Research & Development Bvba

20140193497 - Taste-masked pharmaceutical compositions containing diclofenac: A pharmaceutical composition is described which includes diclofenac as an active ingredient. The pharmaceutical composition further includes a (meth)acrylic polymer which has a specific solubility and/or a particular functional group in one polymer component.... Agent: Glatt Ag

20140193498 - Compositions and methods for treating metabolic disorders: Compositions and methods for improving the pharmacokinetics and reducing the risk of adverse events resulting from biguanide compound administration are provided, comprising administering delayed release formulations of such compounds having a lag phase release.... Agent:

20140193503 - Aqueous suspension concentrate comprising an acid salt of dodecylguanidine: The invention concerns a suspension concentrate comprising, expressed by weight based on the total weight of the composition: a) 40 to 80% particles of dodecylguanidine or an acid salt of dodecylguanidine of the structure (1), wherein X represents an acid residue of a monocarboxylic, dicarboxylic or a mineral acid, b)... Agent: Agriphar S.a.

20140193499 - Bioactive glass composition, its applications and respective preparation methods: The present invention relates to development of bioactive glass/glass-ceramic composition that are able to promote a fast deposition layer of carbonated hydroxyapatite upon immersion in simulated body fluid (SBF) for time periods as short as one hour. Such composition might include fluorides, and a variety of oxides (or their precursor... Agent: Reg4life Regeneration Technology, S.a.

20140193500 - Dry shampoo comprising urea-formaldehyde: A method of treating hair and/or skin of a human or animal, the method comprising applying to the hair and/or skin a composition comprising particles of a urea formaldehyde polymer wherein the particles have an average size of less then 300 microns; an oil absorption value of greater than 40... Agent:

20140193502 - Foam prepared from nanoemulsions and uses: The present invention provides a foamable composition for administration to the skin, body surface, body cavity or mucosal surface, e.g., the mucosa of the nose, mouth, eye, ear, respiratory system, vagina or rectum, and methods of using such a composition to treat, alleviate, or prevent a disorder of the skin,... Agent: Foamix Ltd.

20140193501 - Pulmonary delivery in treating disorders of the central nervous system: A method for treating a disorder of the central nervous system includes administering to the respiratory tract of a patient a drug which is delivered to the pulmonary system, for instance to the alveoli or the deep lung. The drug is administered at a dose which is at least about... Agent: Civitas Therapeutics, Inc.

20140193504 - Polymer-drug systems: The present disclosure generally relates to polymer-drug systems, and more particularly to nanoscopic particles comprising amphiphilic block copolymers conjugated, physically encapsulated, or otherwise combined with chemotherapeutic agents along a selective region or regions of the backbone of the copolymer, so as to package the chemotherapeutic agent in selective domains within... Agent:

20140193505 - Biodegradable carrier with adjustable zeta potentials and particle sizes, method for making the same, and pharmaceutical composition comprising the same: The present invention is related to a biodegradable carrier with adjustable zeta potentials and particle sizes, a method for making the same, and a pharmaceutical composition comprising the same. In such a method, a first solution comprising a first biodegradable macromolecule is prepared, and a second solution comprising a second... Agent:

20140193509 - Carrier pellets, method for production thereof and use thereof: The invention relates to a method for the production of carrier pellets for pharmaceutical active substances. Likewise, the invention relates to such carrier pellets and also to pharmaceutical formulations containing these. The carrier pellets according to the invention are used for transporting and releasing pharmaceutical active substances, in particular in... Agent: Ipc Process-center Gmbh & Co. Kg

20140193507 - Preparation of injectable suspensions having improved injectability: Injectable compositions having improved injectability. The injectable compositions include microparticles suspended in an aqueous injection vehicle having a viscosity of at least 20 cp at 20° C. The increased viscosity of the injection vehicle that constitutes the fluid phase of the suspension significantly reduces in vivo injectability failures. The injectable... Agent: Alkermes Controlled Therapeutics, Inc.

20140193506 - Protection against influenza infection by granulocyte-macrophage colony stimulating factor: Alveolar macrophages contribute to host defenses against influenza. Enhancing their function contributed to protection against influenza and other acute lethal pulmonary infections. Wild-type mice and Tg mice expressing GM-CSF in the lung were infected with influenza virus, and lung pathology, weight loss and mortality were measured. GM-CSF was also administered... Agent: Board Of Regents, The University Of Texas System

20140193508 - Surface binding of nanoparticle based drug delivery to tissue: Microparticles and nanoparticles and compositions thereof are provided. The microparticles and nanoparticles and compositions may be used for the treatment of musculoskeletal disease, such as osteoarthritis and injury.... Agent: Massachusetts Institute Of Technology

20140193510 - Polymer-agent conjugates, particles, compositions, and related methods of use: Described herein are polymer-agent conjugates and particles, which can be used, for example, in the treatment of cancer. Also described herein are mixtures, compositions and dosage forms containing the particles, methods of using the particles (e.g., to treat a disorder), kits including the polymer-agent conjugates and particles, methods of making... Agent: Cerulean Pharma Inc.

20140193511 - Compositions of functional mitochondria and uses thereof: Mitochondrial compositions and therapeutic methods of using same. Compositions of partially purified functional mitochondria and methods of using the compositions to treat conditions which benefit from increased mitochondrial function by administering the compositions to a subject in need thereof.... Agent: Minovia Therapeutics Ltd.

20140193512 - Clotting cascade initiating apparatus and methods of use and methods of closing wounds: Wound closure methods and apparatuses are provided which utilize blood fluid by activating the clotting cascade of the blood fluid outside the body within a substantially enclosed sterile container then introducing coagulated blood to the wound site to complete clotting. Methods and apparatuses for providing ways of inhibiting anticoagulants and... Agent: Closys Corporation

20140193513 - Method for solubilising, dispersing and stabilising of substances, products manufactured according to the method as well as the use thereof: Disclosed is a method in which poloxamer, a resin, and/or a tocopherol is/are fused, and the material that is to be treated is intimately dispersed with said melt. After being introduced into the melt, the material that is to be treated is coated with water to prevent hardening, and the... Agent: Biorem Ag

20140193514 - Method for the treatment of cancer: The invention describes a method to treat an extracorporeally body fluid. The body fluid can include, for example, blood, cerebral spinal fluid and lymph. A first stage of the method applies a treatment to the extracorporeal body fluid. The treatment comprises combining at least one antibody with a CA antigen... Agent: Marv Enterprises

20140193515 - Colloidal collagen burn wound dressing produced from jellyfish: The present invention relates to methods of forming wound dressings from jellyfish collagen. A jellyfish tissue is provided, after which an acid is added to produce a collagen-salt solution. The solution is mixed to form a viscous colloidal gel, and a film or a film/fabric composite is created from the... Agent: Coll-med, Ltd.

20140193516 - Methods for treating glucose metabolic disorders: In one aspect, the invention relates to methods for treating a disease or condition associated with abnormal glucose metabolism. In another aspect, the invention relates to a method for reducing incidence or progression of insulin-dependent diabetes mellitus. The methods include orally administering to a mammal in need thereof an effective... Agent:

20140193517 - Method of drug repositioning: Methods are provided for selecting a new therapeutic indication for at least one first pharmaceutical comprising the steps of: generating a drug-side effect (SE) association for said at least one first pharmaceutical; generating a disease-side effect (SE) association for at least one disease or disorder and at least one second... Agent: Glaxosmithkline Intellectual Property Development Limited

20140193518 - Kinase inhibitor compounds: The invention relates to kinase inhibitor compounds and methods of identifying and using them. The invention further relates to pharmaceutical compositions and methods for treating disorders, especially cancer.... Agent: University Of Florida Research Foundation, Inc.

20140193519 - Indibulin therapy: The invention provides combination therapy, wherein one or more other therapeutic agents are administered with indibulin or a pharmaceutically acceptable salt thereof and the combination is synergistic. Another aspect of the invention relates to the treatment of cancer with indibulin as a single agent. Another aspect of the invention relates... Agent: Ziopharm Oncology, Inc.

20140193521 - Drug delivery systems and method of reducing foal infection by treating mares with gallium salts: This invention relates to drug delivery systems and methods of preventing respiratory bacterial infection in a foal of a mare. This invention relates to the reduction of transmission from the mare to the foal of bacteria though contaminated matter in the foal's environment.... Agent:

20140193520 - Growth control of oral and superficial organisms using gallium compounds: The present invention provides methods for treating or preventing diseases and disorders caused by iron-dependent pathogenic microorganisms, such as bacteria, fungi, and parasites, by applying a gallium compound to an affected area. In particular, the present invention provides methods for treating or preventing dental caries, vaginal infections, skin infections, and... Agent: Mount Sinai School Of Medicine

20140193522 - Mixtures for producing chlorine dioxide gas in enclosures and methods of making the same: The present disclosure relates to a mixture for producing chlorine dioxide gas provided in an enclosure comprising an impregnate comprising a chlorine dioxide precursor impregnated in a porous carrier and a proton-generating species, wherein the impregnate and proton-generating species are intermixed to produce a stable mixture and the mixture is... Agent: Ica Trinova, LLC

20140193523 - Pharmaceutical formulations for the treatment and prevention of trauma-induced neuropathology and neurodegeneration: Novel multi-component formulations, procedures and methods for use in treating neuropathology and neurodegeneration incident to trauma are provided. Multi-component formulations of the invention comprise biologically active forms of any two, any three, or all four of at least one neurosteroid or neuroactive steroid, such as progesterone or synthetic progestin, at... Agent:

20140193524 - Method and composition for the treatment of skin conditions: The present invention relates to artificial seawater and its use to treat a variety of skin conditions, when that sea water has more magnesium in it than in naturally occurring seawater. The treatment of acne and the like can be improved with the product of the present invention.... Agent:

20140193525 - Methods for treating or preventing radiocontrast agent induced kidney injury: Methods for treating or preventing radiocontrast agent induced kidney injury in a mammal are disclosed, the methods comprising administering to the mammal a first effective amount of a chalcogenide composition prior to administering a radiocontrast agent to the mammal.... Agent: Fred Hutchinson Cancer Research Center

20140193527 - Formulations, methods and procedures for reducing or preventing the development, or the risk of development, of neuropathology as a result of trauma: Novel formulations and methods for their use in treating neuropathology incident to trauma are provided. Multiple-component formulations of the invention, and especially those having four components, comprise biologically active compounds configured for preventing or reducing the incidence and severity of damage caused by neurotrauma. Formulations and methods of the invention... Agent:

20140193526 - Formulations, procedures, methods and combinations thereof for reducing or preventing the development, or the risk of development, of neuropathology as a result of trauma: Novel formulations and methods for their use in treating neuropathology incident to trauma are provided. Multiple-component formulations of the invention, and especially those having four components, comprise biologically active compounds configured for preventing or reducing the incidence and severity of damage caused by neurotrauma. Formulations and methods of the invention... Agent:

20140193528 - Three-component formulations, methods and procedures, and combinations thereof, for reducing or preventing the development, or the risk of development, of neuropathology resulting from trauma: Novel three-component formulations, procedures and methods for use in treating neuropathology incident to trauma are provided. Three-component formulations of the invention comprise biologically active forms of at least one neurosteroid, at least one anti-epileptic or anticonvulsant, and at least one lithium-containing or lithium-related compound. The provided formulations are configured or... Agent:

20140193529 - Modulation of thymosin beta-4 in skin: Methods for preventing, ameliorating, or reducing dermatological signs of inflammation are provided which employ active agents, other than a retinoid, that stimulate thymosin beta-4 expression in the skin and inhibit production of pro-inflammatory chemokines and/or cytokines. Also provided are methods for screening for substances which stimulate thymosin beta-4 expression levels... Agent: Avon Products, Inc.

20140193530 - Pharmaceutical composition containing honeysuckle extract and antibiotics, pharmaceutical kit, and use of honeysuckle extract for preparation of drug: Provided is a pharmaceutical composition useful for prevention and/or treatment of diseases caused by bacteria, wherein the pharmaceutical composition comprising a honeysuckle extract containing iridoid compounds and an antibiotic. Also provided is a pharmaceutical kit comprising the honeysuckle extract containing the iridoid compounds and the antibiotics which are separately placed.... Agent:

20140193531 - Aqueous extracts of deschampsia antarctica: In another embodiment the present invention provides a method of treatment for the prevention of photoaging effects generated by exposure to harmful ultraviolet radiation comprising the step of administering to a human being a therapeutically effective amount of the aqueous extract of D. Antarctica. Preferably the extract is administered in... Agent: Uxmal S.a

20140193532 - Complementary personal lubricant compositions: This invention relates to novel compositions and methods of use by which the compositions of this invention are applied topically to one or more body parts of at least two individuals who bring said body parts into contact with the other individual and, when said body parts come into contact... Agent: Mcneil-ppc, Inc.

20140193533 - Formulation of curcuminoids with enhanced bioavailability of curcumin, demethoxycurcumin, bisdemethoxycurcumin and method of preparation and uses thereof: A formulation of curcuminoid mixture having curcumin, demethoxycurcumin and bisdemethoxycurcumin and an essential oil of turmeric having 45% Ar-turmerone. The formulation gives enhanced bioavailability of bisdemethoxycurcumin, demethoxycurcumin and curcumin for up to 10 hrs. The curcuminoid mixture has curcumin, demethoxycurcumin and bisdemethoxycurcumin in a weight/weight ratio ranging from about 0.8:1:1... Agent:

20140193534 - Epicatechin for alleviating symptoms of allergy: The present invention relates to epicatechin for use in the prevention or reduction of symptoms of an allergic disorder and/or an allergic reaction. The invention further relates to epicatechin for said use in the form of food, food product, food supplement or pharmaceutical products.... Agent: Nestec S.a.

  
  
  
Previous industry: Chemistry of inorganic compounds
Next industry: Plastic article or earthenware shaping or treating: apparatus


######

RSS FEED for 20140710: xml
Integrate FreshPatents.com into your RSS reader/aggregator or website to track weekly updates.
For more info, read this article.

######

Thank you for viewing Drug, bio-affecting and body treating compositions patents on the FreshPatents.com website. These are patent applications which have been filed in the United States. There are a variety ways to browse Drug, bio-affecting and body treating compositions patent applications on our website including browsing by date, agent, inventor, and industry. If you are interested in receiving occasional emails regarding Drug, bio-affecting and body treating compositions patents we recommend signing up for free keyword monitoring by email.



Results in 0.85594 seconds

PATENT INFO